110 related articles for article (PubMed ID: 19402389)
1. Diagnostic and prognostic impact of p63 immunoreactivity in renal malignancies.
Tuna B; Unlu M; Aslan G; Secil M; Yorukoglu K
Anal Quant Cytol Histol; 2009 Apr; 31(2):118-22. PubMed ID: 19402389
[TBL] [Abstract][Full Text] [Related]
2. p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system.
Carvalho JC; Thomas DG; McHugh JB; Shah RB; Kunju LP
Histopathology; 2012 Mar; 60(4):597-608. PubMed ID: 22260386
[TBL] [Abstract][Full Text] [Related]
3. P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors.
Langner C; Ratschek M; Tsybrovskyy O; Schips L; Zigeuner R
J Histochem Cytochem; 2003 Aug; 51(8):1097-9. PubMed ID: 12871991
[TBL] [Abstract][Full Text] [Related]
4. PAX8 (+)/p63 (-) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract.
Albadine R; Schultz L; Illei P; Ertoy D; Hicks J; Sharma R; Epstein JI; Netto GJ
Am J Surg Pathol; 2010 Jul; 34(7):965-9. PubMed ID: 20463571
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
[TBL] [Abstract][Full Text] [Related]
6. Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma.
Jou YC; Tsai YS; Hsieh HY; Chen SY; Tsai HT; Chen KJ; Wang ST; Shiau AL; Wu CL; Tzai TS
Urol Oncol; 2013 Nov; 31(8):1806-11. PubMed ID: 22609059
[TBL] [Abstract][Full Text] [Related]
7. The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas.
Gonzalez-Roibon N; Albadine R; Sharma R; Faraj SF; Illei PB; Argani P; Ertoy D; Allaf ME; Netto GJ
Hum Pathol; 2013 Dec; 44(12):2651-7. PubMed ID: 24071011
[TBL] [Abstract][Full Text] [Related]
8. Ezrin immunoreactivity in renal cell carcinomas.
Tuna B; Yorukoglu K; Mazzucchelli R; Mungan U; Secil M; Montironi R; Kirkali Z
Anal Quant Cytol Histol; 2009 Oct; 31(5):340-4. PubMed ID: 20701102
[TBL] [Abstract][Full Text] [Related]
9. The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma.
Lin X; Zhu B; Villa C; Zhong M; Kundu S; Rohan SM; Yang XJ
Hum Pathol; 2014 Sep; 45(9):1824-9. PubMed ID: 24993315
[TBL] [Abstract][Full Text] [Related]
10. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
11. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
12. Renal tumor with alpha B crystallin expression.
Kim MS; Lee HW; Lee EH
Int J Clin Exp Pathol; 2015; 8(8):9383-9. PubMed ID: 26464692
[TBL] [Abstract][Full Text] [Related]
13. Primary carcinoma of renal calyx.
Williams PA; Mai KT
Pathol Res Pract; 2013 Oct; 209(10):654-61. PubMed ID: 23999038
[TBL] [Abstract][Full Text] [Related]
14. CD10 is a diagnostic and prognostic marker in renal malignancies.
Langner C; Ratschek M; Rehak P; Schips L; Zigeuner R
Histopathology; 2004 Nov; 45(5):460-7. PubMed ID: 15500649
[TBL] [Abstract][Full Text] [Related]
15. GATA3 immunohistochemical expression in invasive urothelial carcinoma.
Mohammed KH; Siddiqui MT; Cohen C
Urol Oncol; 2016 Oct; 34(10):432.e9-432.e13. PubMed ID: 27241168
[TBL] [Abstract][Full Text] [Related]
16. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma.
Lidgren A; Hedberg Y; Grankvist K; Rasmuson T; Vasko J; Ljungberg B
Clin Cancer Res; 2005 Feb; 11(3):1129-35. PubMed ID: 15709180
[TBL] [Abstract][Full Text] [Related]
17. [Characterization and staging of renal tumors: significance of MRI diagnostics].
Kalinka A; Gerlach A; Arlart IP; Günes N; Hauser TK; Würstlin S; Bosse A
Rofo; 2006 Mar; 178(3):298-305. PubMed ID: 16508837
[TBL] [Abstract][Full Text] [Related]
18. Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer.
Wan YP; Xi M; He HC; Wan S; Hua W; Zen ZC; Liu YL; Zhou YL; Mo RJ; Zhuo YJ; Luo HW; Jiang FN; Zhong WD
Oncol Res Treat; 2017; 40(1-2):15-20. PubMed ID: 28118628
[TBL] [Abstract][Full Text] [Related]
19. WWOX protein expression varies among RCC histotypes and downregulation of WWOX protein correlates with less-favorable prognosis in clear RCC.
Lin JT; Tzai TS; Liao CY; Wang JS; Wu TT; Wang HY; Wu CH; Yu CC; Lu PJ
Ann Surg Oncol; 2013 Jan; 20(1):193-9. PubMed ID: 22555346
[TBL] [Abstract][Full Text] [Related]
20. PLAGL1 (ZAC1/LOT1) Expression in Clear Cell Renal Cell Carcinoma: Correlations with Disease Progression and Unfavorable Prognosis.
Godlewski J; Krazinski BE; Kowalczyk AE; Kiewisz J; Kiezun J; Kwiatkowski P; Sliwinska-Jewsiewicka A; Maslowski Z; Kmiec Z
Anticancer Res; 2016 Feb; 36(2):617-24. PubMed ID: 26851016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
